The present application provides a Chondroitinase ABC (ChABC) mutants. ChABC stimulates axonal regeneration by degrading the inhibitory chondroitin sulfate (CS) and dermatan sulfate (DS) proteoglycans in the glial scar that forms after traumatic injuries to the central nervous system (CNS). However, the therapeutic utility of this potent, fragile protein is severely limited by rapid aggregation at physiological temperature. To overcome this limitation, the ChABC mutants were engineered to at least 15 point mutations in domain 2 of the wild-type ChABC and/or at least 5 point mutations in domain 3 of the wild-type enzyme. These mutants exhibit improved stability over wild-type ChABC. The present application further provides method and compositions comprising the mutant ChABC for treating conditions associated with excess proteoglycan formation or conditions for which treatment is benefitted by degradation of proteoglycans, including CNS injuries, scarring and cancer.

There are provided a pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/μg as an active ingredient, and containing the saccharide-degrading enzyme in an amount of not less than 2 μg and not more than 8 μg.

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

A pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/μg as an active ingredient, and contains the saccharide-degrading enzyme in an amount of not less than 2 μg and not more than 6 μg.

Described herein are targeted ChABC fusion proteins, complexes thereof, and uses thereof. The targeted ChABC fusion proteins can include a ChABC polypeptide that can be linked to a Gal-3 polypeptide. Monomer targeted ChABC fusion proteins can form homogeneous or heterogeneous complexes. The targeted ChABC fusion proteins and complexes thereof can be formulated as pharmaceutical formulations. The targeted ChABC fusion proteins, complexes thereof, and formulations thereof can be administered to a subject in need thereof.

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.

There are provided a pharmaceutical composition containing a lyophilized saccharide-degrading enzyme having excellent titer, and a package containing the pharmaceutical composition. The pharmaceutical composition is a unit dose formulation containing a lyophilized saccharide-degrading enzyme with a titer of not less than 0.3 unit/g as an active ingredient, and containing the saccharide-degrading enzyme in an amount of not less than 2 g and not more than 8 g.

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.

The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.